Johnson & Johnson signals 2026 sales midpoint of $100.6B and adjusted operational EPS of $11.50-$11.65, driven by new launches

EarningsPositive

AI Analysis

Summary

Johnson & Johnson provided 2026 financial guidance with sales midpoint of $100.6B and adjusted operational EPS of $11.50-$11.65, driven by anticipated new product launches.

Financial Highlights

Revenue

$100.6B

EPS

$11.50-$11.65

Guidance

2026 sales midpoint $100.6B, adjusted operational EPS $11.50-$11.65

Importance:5/10

Sentiment:

0.50

guidancesales forecastearningsnew product launches

Related Companies

$JNJ

Read the original article

Published by Seeking Alpha Healthcare on July 15, 2026 7:58 PM

Read Original